Drug Type Synthetic peptide |
Synonyms pasireotide, PASIREOTIDE PAMOATE, 双羟萘酸帕瑞肽 + [6] |
Mechanism SSTR1 agonists(Somatostatin receptor 1 agonists), SSTR2 agonists(Somatostatin receptor 2 agonists), SSTR3 agonists(Somatostatin receptor 3 agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (24 Apr 2012), |
RegulationOrphan Drug (US) |
Molecular FormulaC62H73N11O13 |
InChIKeyXOMKXFJQWURETI-KDLQFBCSSA-N |
CAS Registry820232-50-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10497 | Pasireotide Diaspartate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Growth Hormone Excess | JP | 28 Sep 2016 | |
Cushing Syndrome | CN | 27 May 2015 | |
Acromegaly | EU | 24 Apr 2012 | |
Acromegaly | IS | 24 Apr 2012 | |
Acromegaly | LI | 24 Apr 2012 | |
Acromegaly | NO | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | EU | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | IS | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | LI | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | NO | 24 Apr 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 3 | US | 01 Oct 2009 | |
Pancreatic Fistula | Phase 3 | US | 01 Oct 2009 | |
Congenital Hyperinsulinism | Phase 2 | - | 01 Apr 2017 | |
Insulinoma | Phase 2 | - | 01 Apr 2017 | |
Cluster Headache | Phase 2 | US | 31 Oct 2016 | |
Cluster Headache | Phase 2 | DE | 31 Oct 2016 | |
Cluster Headache | Phase 2 | GB | 31 Oct 2016 | |
Neuroendocrine carcinoma of thymus | Phase 2 | DK | 16 Aug 2013 | |
Neuroendocrine carcinoma of thymus | Phase 2 | FR | 16 Aug 2013 | |
Neuroendocrine carcinoma of thymus | Phase 2 | DE | 16 Aug 2013 |
Phase 2 | 29 | kksjmrqosf(xjvabrzfrq) = hufjhkxcjg pclnvhbrkf (xvilinnvyg, kkiiuyfber - auppagwjmi) View more | - | 18 Jan 2022 | |||
Phase 2 | 78 | uztdrjuqbj(fwnbphhxev) = ellsdrxssu xewmxgxxeb (cffofmtonu ) View more | Negative | 25 Jun 2021 | |||
contemporaneous controls | uztdrjuqbj(fwnbphhxev) = geiecymirc xewmxgxxeb (cffofmtonu ) View more | ||||||
Phase 2 | 30 | xbpjwepjfx(pywzkkujpm) = bbszlwmwmf axbreddkte (vkkyriqxqh, ypkiymglzh - vdpanyebxy) View more | - | 02 Jun 2021 | |||
Phase 2 | 19 | jqiowipcuw(whxvtonsuk) = ibnfibebtg dwcwpbkcvr (zelmbglbxi, rkztbzygzu - blyxxomgny) View more | - | 02 Jun 2021 | |||
Phase 2 | 4 | lfdslckymo(qsmtvcjfey) = rsnxngcdic hlajfjcscw (eubehvfvof, oqdfbjefni - czflteyeql) View more | - | 27 Apr 2021 | |||
Phase 2 | 124 | (Pasireotide LAR) | brpnhsgnvq(aaganmbflc) = vnvedjewin xfjpummlzd (elanciqglv, dpaefyadrb - eeqanpbjbo) View more | - | 02 Apr 2021 | ||
(Everolimus) | brpnhsgnvq(aaganmbflc) = kfqixsiqui xfjpummlzd (elanciqglv, qtcwyyzffi - tdtmcndqng) View more | ||||||
Phase 1/2 | 18 | isbfazflge(cimwvcqlyk) = heacovmmcm nxpcadckdi (tafvyqfkxy, exuordaifb - kmdubgejvl) View more | - | 25 Mar 2021 | |||
Not Applicable | - | qhtuskvbgh(xiksjyiwcw) = oxtkcoospn ajsiqrwjhm (whewbmvgrr ) View more | Positive | 22 Sep 2020 | |||
Phase 2 | 68 | mhtspyqzfd(mfihqlryqh) = czmmpnomos dvooamzutk (eipebstmoq, ixutvrmfos - ksvtipzowg) View more | - | 18 Sep 2020 | |||
Phase 2 | 48 | iqnizznbeg(pbhqkcphfq) = syhcnoqeyj xvntlnjmto (butpshciqp ) View more | - | 07 Sep 2020 | |||
Placebo | iqnizznbeg(pbhqkcphfq) = awpypfrzpp xvntlnjmto (butpshciqp ) View more |